Section Arrow
ABCL.NASDAQ
- AbCellera Biologics
Quotes are at least 15-min delayed:2026/03/20 04:04 EDT
Pre Market
Last
 3.56
+0.03 (+0.85%)
Bid
3.53
Ask
3.59
High 3.56 
Low 3.56 
Volume
Regular Hours (Closed)
Last
 3.53
+0.01 (+0.28%)
Day High 
3.585 
Prev. Close
3.52 
1-M High
3.835 
Volume 
2.41M 
Bid
3.53
Ask
3.59
Day Low
3.39 
Open
3.44 
1-M Low
2.965 
Market Cap 
1.05B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.54 
20-SMA 3.47 
50-SMA 3.64 
52-W High 6.515 
52-W Low 1.8906 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.49/-0.92
Enterprise Value
1.19B
Balance Sheet
Book Value Per Share
3.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
75.13M
Operating Revenue Per Share
0.17
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SERSerina Therapeutics2.48+1.2+93.75%-- 
Pre Market 2.39 -0.09 -3.63%
AZTRAzitra0.1761+0.0394+28.82%-- 
Pre Market 0.2545 +0.0784 +44.52%
HUMAHumacyte0.8541-0.2059-19.42%-- 
Pre Market 0.91 +0.0559 +6.54%
GERNGeron Corp1.55------ 
Pre Market 1.56 +0.01 +0.65%
IBRXImmunityBio8.82+0.26+3.04%-- 
Pre Market 8.86 +0.04 +0.45%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.